• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

现有的匹兹堡化合物 B 正电子发射断层扫描阈值过高:统计和病理评估。

Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.

机构信息

1 Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley CA, USA

1 Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley CA, USA 2 Lawrence Berkeley National Laboratory, Berkeley, California, USA 3 Memory and Aging Centre, Department of Neurology, University of California, San Francisco, USA.

出版信息

Brain. 2015 Jul;138(Pt 7):2020-33. doi: 10.1093/brain/awv112. Epub 2015 May 6.

DOI:10.1093/brain/awv112
PMID:25953778
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4806716/
Abstract

Amyloid-β, a hallmark of Alzheimer's disease, begins accumulating up to two decades before the onset of dementia, and can be detected in vivo applying amyloid-β positron emission tomography tracers such as carbon-11-labelled Pittsburgh compound-B. A variety of thresholds have been applied in the literature to define Pittsburgh compound-B positron emission tomography positivity, but the ability of these thresholds to detect early amyloid-β deposition is unknown, and validation studies comparing Pittsburgh compound-B thresholds to post-mortem amyloid burden are lacking. In this study we first derived thresholds for amyloid positron emission tomography positivity using Pittsburgh compound-B positron emission tomography in 154 cognitively normal older adults with four complementary approaches: (i) reference values from a young control group aged between 20 and 30 years; (ii) a Gaussian mixture model that assigned each subject a probability of being amyloid-β-positive or amyloid-β-negative based on Pittsburgh compound-B index uptake; (iii) a k-means cluster approach that clustered subjects into amyloid-β-positive or amyloid-β-negative based on Pittsburgh compound-B uptake in different brain regions (features); and (iv) an iterative voxel-based analysis that further explored the spatial pattern of early amyloid-β positron emission tomography signal. Next, we tested the sensitivity and specificity of the derived thresholds in 50 individuals who underwent Pittsburgh compound-B positron emission tomography during life and brain autopsy (mean time positron emission tomography to autopsy 3.1 ± 1.8 years). Amyloid at autopsy was classified using Consortium to Establish a Registry for Alzheimer's Disease (CERAD) criteria, unadjusted for age. The analytic approaches yielded low thresholds (standard uptake value ratiolow = 1.21, distribution volume ratiolow = 1.08) that represent the earliest detectable Pittsburgh compound-B signal, as well as high thresholds (standard uptake value ratiohigh = 1.40, distribution volume ratiohigh = 1.20) that are more conservative in defining Pittsburgh compound-B positron emission tomography positivity. In voxel-wise contrasts, elevated Pittsburgh compound-B retention was first noted in the medial frontal cortex, then the precuneus, lateral frontal and parietal lobes, and finally the lateral temporal lobe. When compared to post-mortem amyloid burden, low proposed thresholds were more sensitive than high thresholds (sensitivities: distribution volume ratiolow 81.0%, standard uptake value ratiolow 83.3%; distribution volume ratiohigh 61.9%, standard uptake value ratiohigh 62.5%) for CERAD moderate-to-frequent neuritic plaques, with similar specificity (distribution volume ratiolow 95.8%; standard uptake value ratiolow, distribution volume ratiohigh and standard uptake value ratiohigh 100.0%). A receiver operator characteristic analysis identified optimal distribution volume ratio (1.06) and standard uptake value ratio (1.20) thresholds that were nearly identical to the a priori distribution volume ratiolow and standard uptake value ratiolow. In summary, we found that frequently applied thresholds for Pittsburgh compound-B positivity (typically at or above distribution volume ratiohigh and standard uptake value ratiohigh) are overly stringent in defining amyloid positivity. Lower thresholds in this study resulted in higher sensitivity while not compromising specificity.

摘要

淀粉样蛋白-β(amyloid-β)是阿尔茨海默病的一个标志,早在痴呆症发病前 20 年就开始积累,并且可以通过碳-11 标记的匹兹堡化合物-B 等淀粉样蛋白-β正电子发射断层扫描示踪剂在体内检测到。文献中已经应用了多种阈值来定义匹兹堡化合物-B 正电子发射断层扫描阳性,但这些阈值检测早期淀粉样蛋白-β沉积的能力尚不清楚,并且缺乏将匹兹堡化合物-B 阈值与死后淀粉样蛋白负担进行比较的验证研究。在这项研究中,我们首先使用匹兹堡化合物-B 正电子发射断层扫描,通过四种互补方法为 154 名认知正常的老年人确定了淀粉样蛋白正电子发射断层扫描阳性的阈值:(i)来自 20 至 30 岁年轻对照组的参考值;(ii)基于匹兹堡化合物-B 指数摄取,为每个受试者分配一个为淀粉样蛋白-β阳性或淀粉样蛋白-β阴性的概率的高斯混合模型;(iii)基于不同大脑区域(特征)中匹兹堡化合物-B 摄取的聚类方法,将受试者聚类为淀粉样蛋白-β阳性或淀粉样蛋白-β阴性;(iv)进一步探索早期淀粉样蛋白正电子发射断层扫描信号空间模式的迭代体素分析。接下来,我们在 50 名接受匹兹堡化合物-B 正电子发射断层扫描的个体(正电子发射断层扫描与尸检之间的平均时间为 3.1±1.8 年)中测试了得出的阈值的敏感性和特异性。使用 Consorcium to Establish a Registry for Alzheimer's Disease(CERAD)标准对死后淀粉样蛋白进行分类,未对年龄进行调整。分析方法得出的低阈值(标准摄取比值低=1.21,分布容积比值低=1.08)代表最早可检测到的匹兹堡化合物-B 信号,以及更高的阈值(标准摄取比值高=1.40,分布容积比值高=1.20),在定义匹兹堡化合物-B 正电子发射断层扫描阳性时更为保守。在体素对比中,内侧额皮质首先出现匹兹堡化合物-B 保留增加,然后是楔前叶、外侧额叶和顶叶,最后是外侧颞叶。与死后淀粉样蛋白负担相比,低提议的阈值对 CERAD 中度至频繁的神经突斑块的敏感性高于高阈值(分布容积比值低为 81.0%,标准摄取比值低为 83.3%;分布容积比值高为 61.9%,标准摄取比值高为 62.5%),特异性相似(分布容积比值低为 95.8%,标准摄取比值低为 100.0%)。接收器操作特征分析确定了最佳的分布容积比(1.06)和标准摄取比值(1.20)阈值,与先验的分布容积比低和标准摄取比值低几乎相同。总之,我们发现,匹兹堡化合物-B 阳性的常用阈值(通常为分布容积比高和标准摄取比值高)在定义淀粉样蛋白阳性时过于严格。本研究中的较低阈值导致了更高的敏感性,同时不影响特异性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c448/4806716/971cb3c5cbeb/awv112fig1g.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c448/4806716/971cb3c5cbeb/awv112fig1g.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c448/4806716/971cb3c5cbeb/awv112fig1g.jpg

相似文献

1
Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.现有的匹兹堡化合物 B 正电子发射断层扫描阈值过高:统计和病理评估。
Brain. 2015 Jul;138(Pt 7):2020-33. doi: 10.1093/brain/awv112. Epub 2015 May 6.
2
Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease.年龄、β-淀粉样蛋白沉积和葡萄糖代谢之间的动态关系与阿尔茨海默病的区域易损性相关。
Brain. 2016 Aug;139(Pt 8):2275-89. doi: 10.1093/brain/aww108. Epub 2016 May 13.
3
Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.健康老年人、轻度认知障碍和阿尔茨海默病患者中淀粉样-β沉积的区域动力学:基于 PiB-PET 的纵向研究。
Brain. 2012 Jul;135(Pt 7):2126-39. doi: 10.1093/brain/aws125. Epub 2012 May 23.
4
Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum.跨阿尔茨海默病谱系的β-淀粉样蛋白阶段的临床病理特征及11C-匹兹堡化合物B的意义
Brain. 2015 May;138(Pt 5):1370-81. doi: 10.1093/brain/awv050. Epub 2015 Mar 23.
5
Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.早发性阿尔茨海默病中的淀粉样蛋白负担和代谢功能:顶叶受累。
Brain. 2012 Jul;135(Pt 7):2115-25. doi: 10.1093/brain/aws113. Epub 2012 May 3.
6
Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.氟替卡匹尔PET tau蛋白结合与淀粉样蛋白负荷、临床诊断、年龄和认知之间的关系。
Brain. 2017 Mar 1;140(3):748-763. doi: 10.1093/brain/aww334.
7
Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden.早发性阿尔茨海默病代谢脆弱性的增加与淀粉样蛋白负担无关。
Brain. 2010 Feb;133(Pt 2):512-28. doi: 10.1093/brain/awp326. Epub 2010 Jan 15.
8
Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.使用 18F-THK5105 PET 进行阿尔茨海默病神经纤维缠结的无创评估。
Brain. 2014 Jun;137(Pt 6):1762-71. doi: 10.1093/brain/awu064. Epub 2014 Mar 27.
9
Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.匹兹堡化合物 B 正电子发射断层扫描首位阿尔茨海默病患者的正电子发射断层扫描影像与分子病理学及临床进展的关系。
Brain. 2011 Jan;134(Pt 1):301-17. doi: 10.1093/brain/awq349. Epub 2010 Dec 13.
10
Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue.淀粉样蛋白示踪剂可检测阿尔茨海默病脑组织中的多个结合位点。
Brain. 2013 Jul;136(Pt 7):2217-27. doi: 10.1093/brain/awt142. Epub 2013 Jun 11.

引用本文的文献

1
REM Sleep Misfires: Intruding Delta Waves Forecast Tau, Amyloid, and Forgetting in Aging.快速眼动睡眠失误:侵入性的δ波预示着衰老过程中的tau蛋白、淀粉样蛋白以及遗忘现象。
bioRxiv. 2025 Aug 22:2025.08.18.670879. doi: 10.1101/2025.08.18.670879.
2
Comparison of Radiomics and conventional SUVr methods for Alzheimer's disease classification using AV45 PET imaging.使用AV45正电子发射断层显像(PET)成像技术,比较基于影像组学和传统标准化摄取值比率(SUVr)方法对阿尔茨海默病进行分类的效果。
Front Neurol. 2025 Aug 6;16:1594470. doi: 10.3389/fneur.2025.1594470. eCollection 2025.
3
Genetic Correlates of Presenile Dementia and Cognitive Decline in the Armenian Population Following COVID-19: A Case-Control Study.

本文引用的文献

1
Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.放射性氟 18 标记的氟曲美他胺的 3 期临床试验与神经纤维缠结密度成像。
JAMA Neurol. 2015 Mar;72(3):287-94. doi: 10.1001/jamaneurol.2014.4144.
2
The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.百分制项目:通过正电子发射断层扫描(PET)实现定量淀粉样斑块评估的标准化。
Alzheimers Dement. 2015 Jan;11(1):1-15.e1-4. doi: 10.1016/j.jalz.2014.07.003. Epub 2014 Oct 28.
3
Comorbidity in dementia: update of an ongoing autopsy study.
COVID-19 后亚美尼亚人群早老性痴呆和认知衰退的遗传相关性:一项病例对照研究
Int J Mol Sci. 2025 Jul 20;26(14):6965. doi: 10.3390/ijms26146965.
4
Performance change while learning novel cognitive tasks as a potential identifier of preclinical Alzheimer's disease.学习新认知任务时的表现变化作为临床前阿尔茨海默病的潜在识别指标。
J Alzheimers Dis Rep. 2025 Jul 15;9:25424823251356597. doi: 10.1177/25424823251356597. eCollection 2025 Jan-Dec.
5
Evaluation of plasma p-tau217 for detecting amyloid pathology in a heterogeneous community-based cohort.评估血浆p-tau217在基于社区的异质队列中检测淀粉样蛋白病理的作用。
Alzheimers Dement. 2025 Jul;21(7):e70426. doi: 10.1002/alz.70426.
6
Characterizing spatiotemporal white matter hyperintensity pathophysiology in vivo to disentangle vascular and neurodegenerative contributions.在体内表征白质高信号的时空病理生理学,以厘清血管和神经退行性病变的影响。
medRxiv. 2025 Jun 11:2025.06.10.25329342. doi: 10.1101/2025.06.10.25329342.
7
Basal forebrain volume is associated with cortical amyloid burden in cognitively unimpaired older adults at varying genetic risk for Alzheimer's disease.在患阿尔茨海默病遗传风险各异的认知未受损老年人中,基底前脑体积与皮质淀粉样蛋白负荷相关。
bioRxiv. 2025 Jun 1:2025.05.28.656557. doi: 10.1101/2025.05.28.656557.
8
A brief history of Aβ imaging.Aβ成像简史。
Alzheimers Dement. 2025 May;21(5):e70291. doi: 10.1002/alz.70291.
9
Brain Topological Changes in Subjective Cognitive Decline and Associations with Amyloid Stages.主观认知衰退中的脑拓扑变化及其与淀粉样蛋白阶段的关联
J Neurosci. 2025 Jun 18;45(25):e2310242025. doi: 10.1523/JNEUROSCI.2310-24.2025.
10
Peripheral Inflammation and Insulin Resistance: Their Impact on Blood-Brain Barrier Integrity and Glia Activation in Alzheimer's Disease.外周炎症与胰岛素抵抗:它们对阿尔茨海默病中血脑屏障完整性和胶质细胞激活的影响。
Int J Mol Sci. 2025 Apr 29;26(9):4209. doi: 10.3390/ijms26094209.
痴呆症中的共病:一项正在进行的尸检研究的更新
J Am Geriatr Soc. 2014 Sep;62(9):1722-8. doi: 10.1111/jgs.12977. Epub 2014 Jul 15.
4
Differential clinicopathologic and genetic features of late-onset amnestic dementias.迟发性遗忘性痴呆的临床病理和遗传特征差异
Acta Neuropathol. 2014 Sep;128(3):411-21. doi: 10.1007/s00401-014-1302-2. Epub 2014 Jun 5.
5
Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease.淀粉样蛋白和 APOE ε4 相互作用影响临床前阿尔茨海默病的短期衰退。
Neurology. 2014 May 20;82(20):1760-7. doi: 10.1212/WNL.0000000000000431. Epub 2014 Apr 18.
6
Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers.阿尔茨海默病的淀粉样蛋白 PET 成像:三种放射性示踪剂的比较。
Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1398-407. doi: 10.1007/s00259-014-2753-3. Epub 2014 Mar 20.
7
Cortical thickness mediates the effect of β-amyloid on episodic memory.皮质厚度介导β-淀粉样蛋白对情景记忆的影响。
Neurology. 2014 Mar 4;82(9):761-7. doi: 10.1212/WNL.0000000000000170. Epub 2014 Jan 31.
8
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.两项评估 bapineuzumab 治疗轻度至中度阿尔茨海默病的 3 期临床试验。
N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839.
9
Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue.淀粉样蛋白示踪剂可检测阿尔茨海默病脑组织中的多个结合位点。
Brain. 2013 Jul;136(Pt 7):2217-27. doi: 10.1093/brain/awt142. Epub 2013 Jun 11.
10
Does a positive Pittsburgh Compound B scan in a patient with dementia equal Alzheimer disease?痴呆患者 Pittsburgh 复合 B 扫描阳性是否等于阿尔茨海默病?
JAMA Neurol. 2013 Jul;70(7):912-4. doi: 10.1001/jamaneurol.2013.420.